XOMA Corporation (XOMA) CEO Sells $356,641.44 in Stock

XOMA Corporation (NASDAQ:XOMA) CEO James R. Neal sold 11,568 shares of XOMA Corporation stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $30.83, for a total transaction of $356,641.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James R. Neal also recently made the following trade(s):

  • On Wednesday, November 15th, James R. Neal sold 46,296 shares of XOMA Corporation stock. The shares were sold at an average price of $28.24, for a total transaction of $1,307,399.04.

XOMA Corporation (NASDAQ:XOMA) opened at $22.90 on Friday. XOMA Corporation has a 12-month low of $3.96 and a 12-month high of $33.00. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53.

ILLEGAL ACTIVITY NOTICE: “XOMA Corporation (XOMA) CEO Sells $356,641.44 in Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/18/xoma-corporation-xoma-ceo-sells-356641-44-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of XOMA. California Public Employees Retirement System lifted its position in XOMA Corporation by 95.5% during the 1st quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 10,640 shares during the period. EAM Investors LLC purchased a new position in XOMA Corporation during the 3rd quarter valued at about $835,000. Finally, OxFORD Asset Management LLP purchased a new position in XOMA Corporation during the 3rd quarter valued at about $543,000. 30.69% of the stock is owned by institutional investors.

XOMA has been the topic of a number of research reports. Zacks Investment Research raised shares of XOMA Corporation from a “sell” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Tuesday, October 17th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of XOMA Corporation in a research report on Tuesday, October 17th. Finally, Wedbush reissued a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. XOMA Corporation presently has a consensus rating of “Buy” and a consensus target price of $30.00.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Insider Buying and Selling by Quarter for XOMA Corporation (NASDAQ:XOMA)

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply